Analysis of the CCL3-L1 gene for association with HIV-1 susceptibility and disease progression.
CCL-L1 binds more potently to CCR5 than any other chemokine; it inhibits HIV-1 infection in vitro, and its gene occurs in variable copy numbers, some individuals failing to produce it. We analysed the frequency of the absence of CCL3-L1 in 268 Caucasian Australian HIV-1 patients and 260 uninfected individuals. A CCL-L1-negative genotype frequency of 2.3% was found in HIV-1 negative individuals. No association was found between the absence of CCL3-L1 and susceptibility to, or rate of progression of, HIV-1 infection.
Bugeja
Matthew J
MJ
Institute for Immunology and Allergy Research, Westmead Millennium Institute, Westmead Hospital, Sydney, NSW, Australia.
Booth
David R
DR
Bennetts
Bruce H
BH
Guerin
Jan
J
Kaldor
John M
JM
Stewart
Graeme J
GJ
D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018450:Disease Progression; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015658:HIV Infections / Q000235:genetics*; D015497:HIV-1; D006801:Humans; D019402:Macrophage Inflammatory Proteins / Q000235:genetics*; D008297:Male
D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins